Collaborations (Tables)

9 Months Ended

Sep. 30, 2012

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]

The following table summarizes the composition of our total revenue recognized from all transactions, including collaboration activity:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2012		2011		2012		2011
	(Dollars in millions)
Net product sales	$	5,301.2	$	5,971.7	$	16,170.5	$	17,748.1
Collaboration and other revenue	142.1		176.2		475.5		491.8
Total revenue	$	5,443.3	$	6,147.9	$	16,646.0	$	18,239.9

Erbitux [Member]

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]

The following table summarizes the revenue recognized with respect to Erbitux:

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2012		2011		2012		2011
	(Dollars in millions)
Net product sales	$	6.2	$	16.2	$	69.0	$	61.2
Collaboration and other revenue	80.4		81.1		241.0		240.1
Total revenue	$	86.6	$	97.3	$	310.0	$	301.3

Exenatide [Member]

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table Text Block]

The following table summarizes the revenue and other income recognized with respect to exenatide: 

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2012		2011		2012		2011
	(Dollars in millions)
Net product sales	$	49.5	$	46.4	$	151.1	$	131.9
Collaboration and other revenue	4.7		60.3		70.1		180.5
Total revenue	$	54.2	$	106.7	$	221.2	$	312.4
Income related to prepayment of Amylin's obligation (1)	$	787.8	$	—	$	787.8	$	—

¹ Presented in other-net, (income) expense